Search

Ion Beam Applications

Open

10.1 -3.81

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.94

Max

10.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

-10M

Verkäufe

206M

KGV

Branchendurchschnitt

41.111

63.778

Dividendenrendite

1.56

Gewinnspanne

-4.99

Angestellte

1,943

EBITDA

-372K

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.56%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

342M

Vorheriger Eröffnungskurs

13.91

Vorheriger Schlusskurs

10.1

Ion Beam Applications Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Sept. 2024, 06:28 UTC

Akquisitionen, Fusionen, Übernahmen

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.